AAAAAA

   
Results: 1-9 |
Results: 9
EGF mutant receptor vIII as a molecular target in cancer therapy
Authors: Kuan, CT Wikstrand, CJ Bigner, DD
Citation: Ct. Kuan et al., EGF mutant receptor vIII as a molecular target in cancer therapy, ENDOCR-R CA, 8(2), 2001, pp. 83-96
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfateMel-14 F(ab ')(2) - A case study
Authors: Cokgor, I Akabani, G Friedman, HS Friedman, AH Zalutsky, MR Zehngebot, LM Provenzale, JM Guy, CD Wikstrand, CJ Bigner, DD
Citation: I. Cokgor et al., Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfateMel-14 F(ab ')(2) - A case study, CANCER, 91(9), 2001, pp. 1809-1813
Radiolabeled antibodies for therapy of brain tumors
Authors: Wikstrand, CJ Zalutsky, MR Bigner, DD
Citation: Cj. Wikstrand et al., Radiolabeled antibodies for therapy of brain tumors, BRAIN TUMOR IMMUNOTHERAPY, 2001, pp. 205-229
Identifying potential tumor markers and antigens by database mining and rapid expression screening
Authors: Loging, WT Lal, A Siu, IM Loney, TL Wikstrand, CJ Marra, MA Prange, C Bigner, DD Strausberg, RL Riggins, GJ
Citation: Wt. Loging et al., Identifying potential tumor markers and antigens by database mining and rapid expression screening, GENOME RES, 10(9), 2000, pp. 1393-1402
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas
Authors: Cokgor, I Akabani, G Kuan, CT Friedman, HS Friedman, AH Coleman, RE McLendon, RE Bigner, SH Zhao, XG Garcia-Turner, AM Pegram, CN Wikstrand, CJ Shafman, TD Herndon, JE Provenzale, JM Zalutsky, MR Bigner, DD
Citation: I. Cokgor et al., Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas, J CL ONCOL, 18(22), 2000, pp. 3862-3872
Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro
Authors: Hedberg, KM Dellheden, B Wikstrand, CJ Fredman, P
Citation: Km. Hedberg et al., Monoclonal anti-GD3 antibodies selectively inhibit the proliferation of human malignant glioma cells in vitro, GLYCOCON J, 17(10), 2000, pp. 717-726
Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor
Authors: McLendon, RE Wikstrand, CJ Matthews, MR Al-Baradei, R Bigner, SH Bigner, DD
Citation: Re. Mclendon et al., Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor, J HIST CYTO, 48(8), 2000, pp. 1103-1110
Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFv
Authors: Kuan, CT Wikstrand, CJ Archer, G Beers, R Pastan, I Zalutsky, MR Bigner, DD
Citation: Ct. Kuan et al., Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFv, INT J CANC, 88(6), 2000, pp. 962-969
Monoclonal antibody therapy of human gliomas: Current status and future approaches
Authors: Wikstrand, CJ Cokgor, I Sampson, JH Bigner, DD
Citation: Cj. Wikstrand et al., Monoclonal antibody therapy of human gliomas: Current status and future approaches, CANC METAST, 18(4), 1999, pp. 451-464
Risultati: 1-9 |